Pharmaceuticals, Biotechnology & Life Sciences

Amgen’s bispecific Imdelltra + Imfinzi boosts overall survival in extensive‑stage small cell lung cancer by 56%, adding 8 months and redefining first‑line therapy.

Insider sales by Natera co‑founder show routine liquidity moves, not distress. Explore how regulatory trends and competitive dynamics shape its long‑term outlook.

Imfinzi’s phase‑III trials show a 8‑month OS boost in extensive‑stage small cell lung cancer and improved peri‑operative survival in muscle‑invasive bladder cancer when paired with bispecific T‑cell engagers or enfortumab‑vedotin, with manageable sa…

Explore how Eli Lilly’s soaring Mounjaro and Zepbound sales are driving 8% revenue growth and why its new ovarian‑cancer ADC and digital‑health M&A plans keep investors bullish.

Genmab and Incyte launch a Phase 1/2 trial combining petosemtamab with KRAS G12D inhibitor INCB161734 to target EGFR, LGR5 and KRAS‑mutated metastatic colorectal cancer.

Explore AstraZeneca’s modest share rise amid AI, oil, and consumer headwinds, and how its clinical pipeline and regulatory milestones shape investor sentiment.

Explore Natera’s October 2026 Form 4: insider sales by co‑founder Sheena Jonathan under a Rule 10b‑5 trading plan, revealing prices, volumes and trust holdings for investors.

Phase 1b data show brezosiran lowers Huntington’s disease mHTT protein by up to 80 % with a safe, well‑tolerated intrathecal regimen, paving the way for a 2027 Phase 3 trial.

Actinium Pharma’s first‑in‑human Phase 1 results for HER3‑targeted ATNM‑400, unveiled at ESMO, could open a new alpha‑therapy path for metastatic prostate cancer.

See how Sartorius AG’s 8% revenue jump and EPS surprise drove a 52‑week high, boosting TecDAX and MDAX amid a volatile German market.